FDA Approved Drug Targeting Changes In Solid Cancers

In a first ever instance, the FDA has granted accelerated approval to pembrolizumab (Keytruda), a cancer drug that could benefit patients with DNA abnormalities such MSI-H and dMMR, notwithstanding the location of the tumor in the body. The safety and efficacy of Pembrolizumab were assessed in patients with solid tumors having MSI-H or dMMR enrolled in one of five single-arm clinical, uncontrolled trials.

Related Links